Active Leukemia Research Projects Worldwide
Explore verified leukemia research projects and clinical trials from leading institutions worldwide. Each project includes detailed investigator profiles, research methodology, and expected outcomes. Find projects covering CAR-T cell therapy, precision medicine, immunotherapy, gene editing, stem cell transplantation, and targeted drug development.
Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management.
Principal Investigator: Dr. Shai Shimony
Institution: Dana-Farber Cancer Institute
Location
Boston, Massachusetts
Timeline
Start: January 2024
Completion: December 2027
PD-1H/VISTA mediates immune evasion in acute myeloid leukemia.
Principal Investigator: Dr. Tae Kon Kim
Institution: Memorial Sloan Kettering Cancer Center
Location
New York, New York
Timeline
Start: January 2023
Completion: December 2026
Advances in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia.
Principal Investigator: Dr. Madelyn Burkart
Institution: Lurie Children's Hospital
Location
Chicago, Illinois
Timeline
Start: January 2023
Completion: December 2026
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.
Principal Investigator: Dr. William G Wierda
Institution: City of Hope Comprehensive Cancer Center
Location
Duarte, California
Timeline
Start: January 2021
Completion: December 2024
Activating STING1-dependent immune signaling in TP53 mutant and wild-type acute myeloid leukemia.
Principal Investigator: Dr. Aksinija A Kogan
Institution: Johns Hopkins Kimmel Cancer Center
Location
Baltimore, Maryland
Timeline
Start: January 2021
Completion: December 2024
NUDT21 limits CD19 levels through alternative mRNA polyadenylation in B cell acute lymphoblastic leukemia.
Principal Investigator: Dr. Matthew T Witkowski
Institution: UCSF Helen Diller Family Comprehensive Cancer Center
Location
San Francisco, California
Timeline
Start: January 2021
Completion: December 2024
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
Principal Investigator: Dr. Vinod A Pullarkat
Institution: City of Hope Comprehensive Cancer Center
Location
Duarte, California
Timeline
Start: January 2020
Completion: December 2023
Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia.
Principal Investigator: Dr. Matthew Mei
Institution: City of Hope Comprehensive Cancer Center
Location
Duarte, California
Timeline
Start: January 2019
Completion: December 2022
Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression.
Principal Investigator: Dr. David A Jacobsohn
Institution: Lurie Children's Hospital
Location
Chicago, Illinois
Timeline
Start: January 2017
Completion: December 2020